This isn’t funding recommendation. The creator has no place in any of the shares talked about. WCCF TECH INC has a disclosure and ethics coverage.
From providing a viable answer to the weight problems pandemic and its comorbidities to decreasing the demand for ResMed’s steady Constructive Airway Strain (PAP) remedy units which can be used to deal with the signs of sleep apnea, it’s hardly stunning that GLP-1 medicine presently represent certainly one of Wall Road’s greatest thematic funding concepts for the continuing decade. Even so, researchers proceed to find new use-cases for these miracle medicine, with the most recent such discovery centering on alcohol habit management.
A Primer On GLP-1 Medicine
The GLP-1 hormone suppresses starvation and regulates the manufacturing of insulin and glucose. After a meal, this hormone raises the extent of insulin, which decreases blood glucose ranges. Concurrently, it reduces the speed at which the abdomen empties its contents into the small gut, creating a sense of fullness and satiation within the course of. Whereas initially billed as a therapy for diabetes, most of the medicine that make the most of GLP-1 agonists are actually bought as a devoted anti-obesity palliative possibility.
See extra
Estimated world weight reduction drug gross sales:
2030: $93.8 billion2029: $77.9 billion2028: $63.7 billion2027: $48.6 billion2026: $35.4 billion2025: $24.6 billion 2024: $14.8 billion2023: $6.3 billion
Supply: Bloomberg Intelligence
— Jon Erlichman (@JonErlichman) June 22, 2024
Novo Nordisk makes use of semaglutide as its proprietary GLP-1 agonist in medicine which can be marketed below Ozempic and Wegovy labels, with the previous geared towards type-2 diabetes and the latter marketed as a therapy for weight problems.
Whereas Novo Nordisk presently has quite a few further GLP-1 medicine within the pipeline, together with these that may be ingested and people who leverage each GLP-1 and Amylin agonists to supply higher efficacy, Wegovy and Ozempic stay the corporate’s major choices for now to deal with weight problems and diabetes.
New Examine: The Semaglutide GLP-1 Agonist Can Considerably Cut back Alcohol Consumption
See extra
1/ GLP-1s WILL HELP YOU KICK ALCOHOL! 🍻 (In case you are a vervet monkey 🐒….for now)
Impact of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys
Common day by day alcohol consumption (g/kg/4 hours) at week 6,… pic.twitter.com/cNHcZl5fmO
— BowTiedBiotech 🧪🔬🧬 (@BowTiedBiotech) June 22, 2024
This brings us to the crux of the matter. Given the optimistic results of the GLP-1 agonists in decreasing nicotine habit, a gaggle of researcher just lately tried to analyze the hormone’s effectiveness in controlling alcohol consumption.
The researchers injected a randomized group of male vervet monkeys with both “escalating doses” (as much as 0.05 mg/kg) of the semaglutide GLP-1 agonist or a placebo twice weekly for 2 weeks. Whereas the monkey had entry to alcohol for 10 days previous to the beginning of the therapy, no alcohol was obtainable throughout these two weeks of therapy. Thereafter, over the next 20 working days, researchers re-introduced alcohol whereas persevering with the twice weekly administration of semaglutide and the placebo.
The GLP-1 agonist Semaglutide was capable of encourage a gaggle of monkeys to drink extra water versus alcohol
In accordance with the outcomes of this examine, semaglutide-treated monkeys drank considerably much less alcohol compared to the management group following the examine’s two-week alcohol drought interval.
After all, this examine solely centered on our mammalian cousins and the GLP-1 agonists won’t be as efficient in controlling alcohol habit in people. It does, nonetheless, open a brand new vector for researchers to discover.